AI reads your Heart's future: new test spots cancer drug danger
NCT ID NCT07515859
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at over 31,000 cancer patients to see if an AI-enhanced electrocardiogram (ECG) could predict heart damage caused by chemotherapy. Researchers analyzed existing ECGs taken before treatment to see if the AI could identify those at risk. The goal is to develop a simple, non-invasive tool to help doctors personalize cancer therapy and prevent heart failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a simple, low-cost ECG test to identify patients at high risk of heart damage before starting cancer therapy.
What could go wrong
This is a retrospective study, not a controlled trial, so results may not apply to all patients. The AI tool needs further validation in prospective studies before clinical use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea